Abnormal cutaneous wound healing can lead to formation of fibrotic hypertrophic scars. Although several clinical risk factors have been described, the cross-talk between different cell types resulting in hypertrophic scar formation is still poorly understood.
burn injury up to 72% of burn patients have hypertrophic scars and 1 year after standard surgery 35% of patients have hypertrophic scars Lawrence, Mason, Schomer, & Klein, 2012; Mahdavian Delavary, van der Veer, Ferreira, & Niessen, 2012; Niessen, Spauwen, Robinson, Fidler, & Kon, 1998; van der Veer et al., 2011) .
Since wounds that form hypertrophic scars are generally full-thickness wounds it is thought that cells from the adipose tissue may contribute to their development (Matsumura et al., 2001; van den Bogaerdt et al., 2009 ). Although several risk factors have been described such as size, depth, and delayed wound closure, the cross-talk between different cell types resulting in hypertrophic scar formation are still poorly understood (Gangemi et al., 2008) .
Normal cutaneous wound healing consists of multiple overlapping phases (Reinke & Sorg, 2012) . Immediately after wounding, a fibrin clot is formed which acts as a provisional matrix. This permits an influx of neutrophils and monocytes into the wound bed thus initiating an inflammatory cascade. During the proliferation phase, re-epithelialization takes place and granulation tissue is formed. Granulation tissue is formed by an accumulation of fibroblasts, capillaries (endothelial cells), immune cells, and collagen bundles. An important part of normal wound healing involves the replacement of the granulation tissue with extracellular matrix and apoptosis of excessive numbers of fibroblasts and endothelial cells (EC) (Johnson & DiPietro, 2013) . Apoptosis of EC ensures that overabundant small blood vessels regress and enables maturation of newly formed networks. Due to the complexity of wound healing, many steps along the way are prone to aberrations and have been described to lead to the formation of hypertrophic scars. For example, delayed re-epithelialization, prolonged inflammation, excessive neovascularization, imbalance of matrix metalloproteinases and their inhibitors, and prolonged presence of myofibroblasts causing excessive extracellular matrix deposition are all related to an increased chance of hypertrophic scar formation (DiPietro, 2016; Mustoe & Gurjala, 2011; Zhu, Ding, & Tredget, 2016) . Also, differences in the organization of the collagen bundles in granulation tissue, where mesenchymal stromal cells (MSC) and EC play an important role, can discriminate between normotrophic scars and hypertrophic scars (Linares, 1996) . Previously we described a hypertrophic scar model in which adipose tissue-derived mesenchymal stromal cells (ASC), when incorporated into a skin equivalent, caused contraction and a hypertrophic phenotype (Boink et al., 2016; van den Broek, Niessen, Scheper, & Gibbs, 2012) . Several studies indicate that changes in vascularization or endothelial dysfunction may play a role in hypertrophic scar formation or regression, respectively (Amadeu et al., 2003; van der Veer et al., 2011; Wang, Song, & Liu, 2017 Xi-Qiao, Ying-Kai, Chun, & Shu-Liang, 2009 ). Also in other organs, for example, in liver and lung, EC have been implicated in formation of fibrotic tissue (Elpek, 2015; Farkas, Gauldie, Voelkel, & Kolb, 2011) . Taken together this suggests that both ASC and EC may be involved in the onset of hypertrophic scar formation.
Transforming growth factor-β1 (TGF-β1) secreted by, for example, platelets, macrophages, keratinocytes, and fibroblasts is associated with fibrosis and scarring (Barrientos, Stojadinovic, Golinko, Brem, & TomicCanic, 2008; Lichtman, Otero-Vinas, & Falanga, 2016) . Increased TGF-β stimulates fibrosis by binding to the ALK5 receptor (TGFβR1) and TGFβR2 and subsequently upregulating type 1 collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression and downregulating matrix metalloproteinase-1 gene expression in fibroblasts leading to enhanced matrix deposition and impaired degradation of extracellular matrix components (Baum & Arpey, 2005; Ghahary, Shen, Scott, & Tredget, 1995; Verrecchia & Mauviel, 2007) . Furthermore, other TGF-β family members have been described as fundamental regulators of inflammation and fibrosis in several organs, such as activin A and B, growth differentiation factor (GDF) 8 and bone morphogenetic proteins (BMP) 2 and 6 (Cantini et al., 2008; Hedger & de Kretser, 2013; Kaiser et al., 1998; Stelnicki et al., 1998; Werner & Alzheimer, 2006) . Activin A, which binds to ALK4 (ACTRIB) and ACTRII or IIB, is thought to exert its effect in fibrosis by upregulation of fibrotic factors TGF-β1, connective tissue growth factor (CTGF), TIMP-1, plasminogen activator inhibitor-1, endothelin and type 1 collagen (Hedger & de Kretser, 2013) .
Interestingly, activin A expression was detected in inflammatory cells during the early phases of burn wound healing, while it was predominantly seen in fibroblasts during later phases of burn wound healing (McLean et al., 2008) . Anti-fibrotic follistatin is primarily known to bind and neutralize activin A with high affinity, but is also able to bind with lower affinity to activin B, GDFs, and BMPs (Amthor et al., 2004; Glister, Kemp, & Knight, 2004; Harrington et al., 2006; Otsuka, Moore, Iemura, Ueno, & Shimasaki, 2001; Schneyer et al., 2008) . These results suggest that activin A, next to TGF-β, plays a key role in fibrosis starting already in the inflammatory and granulation tissue phase of cutaneous wound healing.
Although many studies implicate a role for either ASC or EC in hypertrophic scar formation, the interaction between both cell types and the cross-talk mechanism by which they might stimulate dermal matrix contraction and fibrosis has not been studied. The aim of this study was to investigate the crosstalk between MSC (fibroblast or ASC) and EC in fibrosis in vitro by seeding the cells into a 3D collagen/elastin dermal matrix (MatriDerm®). MSC and EC derived from the dermis were compared with those derived from the adipose tissue in order to determine the influence of wound depth on in vitro fibrosis. 
| MATERIALS AND METHODS

| Human tissue
| Cell culture
Adipose tissue was carefully dissected from the skin. The remaining skin was then treated with dispase to remove the epidermis from the dermis.
The adipose stromal vascular cell fraction and dermal stromal vascular cell fraction were then isolated using collagenase type II/dispase II from adipose tissue or dermis as previously described (Kroeze et al., 2009 
| Mesenchymal stromal cells
ASC and fibroblasts, passage 3, were obtained with 99.9% purity (CD90+, CD31−) and cultured in DMEM (Lonza, Verviers, Belgium), 1% UltroSerG (UG) (BioSepra SA, Cergy-Saint-Christophe, France) and 1% penicillin/ streptomycin (P/S) (Invitrogen, Gibco, Paisley, UK) (Kroeze et al., 2009 ).
| Endothelial cells
EC were purified from the adipose stromal vascular cell fraction (A-EC) and from the dermal stromal vascular cell fraction (D-EC) using a MidiMACS separator with microbeads against CD31 . A >99% pure population (CD31+/CD90−) was obtained at were used to create tissue equivalents as previously described (van den Broek et al., 2012) . This dermal matrix was chosen since it is currently used underneath split-skin autografts for treating full-thickness burns (van Zuijlen et al., 2015) . ASC, fibroblasts, adipose-EC or dermal-EC The tissue equivalents were cultured submerged for 3 weeks in EC medium with addition of 50 μg/ml ascorbic acid and 5 ng/ml epidermal growth factor (Sigma-Aldrich). Culture medium was replaced twice a week. Twenty four hours before harvesting, culture medium was replaced by EC medium without heparin, ECGF and epidermal growth factor for ELISA. The tissue equivalents were harvested for immunohistochemical analysis and mRNA expression.
| Addition of TGF-β1 pathway inhibitors to culture medium
Tissue equivalents were generated as described above with culture medium being supplemented with ALK4/5/7 inhibitor (2 or 10 μM SB431542; Sigma-Aldrich), or recombinant follistatin (0.5 ng/ml follistatin; R&D Systems, Abingdon, UK). Corresponding controls were supplemented with 0.04% DMSO or 0.5% PBS containing 1% BSA.
| Measurement of matrix contraction
Photographs of the tissue equivalents were taken at the start and end of the experiments with a Nikon Coolpix 5400 digital camera (Japan).
The surface areas of the equivalents were measured by NIS-Elements AR 2.10 software.
| Immunohistochemical analysis
Immunohistochemical analysis was performed on paraffin embedded 
| Secretion of granulation tissue formation factors, cytokines, and chemokines
ELISAs were performed using commercially available ELISA antibodies.
All reagents were used in accordance to the manufacturer's specifications. TGF-β1, activin A, follistatin (all R&D Systems). ELISA data are expressed in ng/ml.
| mRNA expression
Upon harvesting the tissue equivalents, a small piece (40-100 mm 
| Statistical analysis
Statistical analyses were performed using t-tests or one-way ANOVA for measurements of contraction or ELISA results. For the PCR data a one-way ANOVA was used followed by a Kruskal Wallis test. All data were obtained from three to seven independent experiments using different donors and duplicate wells. The EC and MSC in each experiment were donor-matched. Differences were considered significant when *p < 0.05, **p < 0.01, ***p < 0.001. Results are shown as mean ± SEM. Taken together these results show that EC derived from either the dermis or adipose tissue induced contraction of tissue equivalents containing ASC, but had no effect on tissue equivalents containing fibroblasts.
| Higher mRNA expression of fibrosis-related genes during co-culture of adipose-EC with ASC
Since relatively little α-SMA expressing cells were observed in tissue equivalents, even in the contractile ones where EC were co-cultured with ASC, it was next determined whether the gene expression of ACTA2 (encoding α-SMA), COL1A1 (encoding collagen 1) and COL3A1 (encoding collagen 3) was altered since these genes have been described to play key roles in excessive matrix formation and hypertrophic scar formation (Sidgwick & Bayat, 2012; van der Veer et al., 2009; Xi-Qiao et al., 2009) (Figure 3 ). ACTA2 was expressed more by fibroblasts and ASC compared to dermal-and adipose-EC.
Moreover, ACTA2 expression was significantly upregulated by tissue equivalents containing co-cultured adipose-EC and ASC compared to co-cultures containing dermal-EC and fibroblasts. A similar trend was seen for COL1A and COL3A. Overall, the tissue equivalent containing co-cultured adipose-EC and ASC showed higher COL1A, COL3A, and ACTA2 than the other tissue equivalents.
| EC stimulate ASC to contract the matrix via the ALK4, ALK5, and ALK7 receptors and reduction of follistatin secretion
To study the underlying molecular pathways involved in the observed contraction of the tissue equivalents containing ASC and EC we next measured secretion of follistatin, activin A, and mRNA expression of TGF-β1 (Figure 4 ). Anti-fibrotic follistatin binds and neutralizes profibrotic activin A and with less affinity also other TGF-β family members. The tissue equivalents containing ASC with or without EC (independent of EC origin) secreted less follistatin than the tissue equivalents containing fibroblasts with or without EC (Figure 4a ), In all tissue equivalents, TGF-β1 secretion was below the detection limit of our ELISA (30 pg/ml; data not shown) therefore we measured the mRNA expression, which was similar in all conditions (Figure 4b ).
In order to further investigate the role of follistatin in our in vitro fibrosis model a broad inhibition of the TGF-β pathway was obtained by blocking the ALK4, ALK5, and ALK7 receptors with the compound SB431542 (Inman et al., 2002) . In tissue equivalents containing cocultured ASC and EC, inhibition of the ALK4/5/7 receptors resulted in dose dependent inhibition of matrix contraction leading to almost complete inhibition (75 ± 11%) ( Figure 5 ). Since follistatin was more expressed in non-contracting tissue equivalents containing fibroblasts (+/− EC) than in contracting tissue equivalents containing ASC-EC we next determined whether the addition of follistatin to ASC-EC tissue equivalents could prevent matrix contraction ( Figure 5 ). Indeed, contraction was significantly decreased by 24 ± 8% when follistatin was added to the culture medium.
Taken together, these results indicate that EC, independent of their dermal or adipose origin, stimulate ASC to contract the matrix via the ALK4, ALK5, and ALK7 receptors of the TGF-β pathway and reduction of follistatin secretion.
| DISCUSSION
The aim of this in vitro study was to investigate whether EC may play a role in skin fibrosis, for example, hypertrophic scar formation after deep skin trauma, where healing arises from the exposed adipose tissue. Using a collagen/elastin matrix routinely used under splitthickness autografts in burn patients (van Zuijlen et al., 2015) , we developed an in vitro fibrosis model to study the specific interaction Altogether our results strengthen the hypothesis that EC contribute to hypertrophic scar formation.
In Figure 6 our proposed scheme of the mechanism by which EC enhance ASC-mediated matrix contraction is shown with follistatin with anti-fibrotic properties and activin A with pro-fibrotic properties (Hedger & de Kretser, 2013 ). Here we show that fibroblasts, isolated from the dermis, secrete more follistatin than ASC isolated from the The contraction of the tissue equivalents which we observed when ASC were co-cultured with EC in the matrix, while no contraction was observed when ASC were cultured alone was already evident within the first week of the 3 week culture period. In line with these findings, we previously showed that a reconstructed epidermis grown on the same ASC-populated matrix also resulted in significant (Boink et al., 2016; van den Broek et al., 2012) . This contraction, in the presence of the reconstructed epidermis coincided with upregulation of α-SMA directly under the epidermis indicating that the ASC had become myofibroblasts.
In our current study we showed that although not many α-SMA positive cells were present in the tissue sections, we did find an upregulation of ACTA2 (α-SMA) at mRNA level. This suggests that either a longer time in co-culture with EC or additional factors from, for example, keratinocytes are required for ASC to fully differentiate into myofibroblasts. It has also been shown that MSC are able to contract tissue in an α-SMA independent manner, via microfilaments (Dawes et al., 2008; Shinde, Humeres, & Frangogiannis, 2017) . TGF-β, activin A and follistatin have been implicated in contraction and fibrosis (Leask & Abraham, 2004; Ohga, Matsuse, Teramoto, & Ouchi, 2000; Werner & Alzheimer, 2006) . By blocking the ALK4/5/7 receptors we observed an almost total inhibition of matrix contraction of tissue equivalents containing both ASC and EC indicating an important role for the TGF-β family. TGF-β1 mRNA was expressed similar by all conditions while TGF-β1 secretion was not detected in the culture supernatants most probably due to direct uptake by neighboring cells. In line with our results, which show a role for EC in enhancing ASC-mediated matrix contraction via the TGF-β pathway, it has been suggested that apoptotic EC can stimulate skin fibrosis via TGF-β regulated CTGF secretion (DiPietro, 2016; Laplante et al., 2010) . We also investigated the role of follistatin and activin A in our model. Activin A, though in small amounts, was secreted by EC independent of their dermal or adipose origin. EC being the source of FIGURE 5 EC stimulate ASC to contract the matrix via follistatin and the ALK4, ALK5, and ALK7 receptors. Surface area when cultured in the absence or presence of 2 μM (+) or 10 μM (++) ALKinhibitor SB431542 or 0.5 ng/ml (+) rh-follistatin, relative to surface area at time 0. Statistical analysis was performed using t-tests or repeated measures one-way ANOVA. *p < 0.05, **p < 0.01. Data are shown for four donors as mean ± SEM. A-EC, adipose-endothelial cells; ASC, adipose-tissue derived mesenchymal stromal cells; D-EC, dermal-endothelial cells; Fib, fibroblasts FIGURE 6 Mechanism of EC enhanced ASC-mediated matrix contraction. (a) Follistatin secreted by fibroblasts sequesters specific members of the TGF-β family, such as activin A, preventing activin A from activating the ALK4 receptor and the downstream fibrogenic target genes, thereby preventing dermal contraction. (b) ASC secrete less follistatin than fibroblasts. Therefore follistatins pro-fibrotic targets are insufficiently sequestered and residual activin/GDF/BMP can activate the ALK4 receptor and the downstream target genes, leading to dermal matrix contraction and fibrosis. (c) By blocking the pathways of the ALK 4/5/7 receptors with SB431542, the proteins of the TGF-β family are prevented from binding to these receptors, leading to a large inhibition of matrix contraction. Addition of recombinant follistatin prevents the binding of activin A to the ALK4 receptor, leading to decreased matrix contraction, but to a lesser extent than SB431542. A-EC, adiposeendothelial cells; ASC, adipose-tissue derived mesenchymal stromal cells; D-EC, dermal-endothelial cells; Fib, fibroblasts; TGF-β, transforming growth factor-β activin A secretion could explain why we only observed contraction in the co-cultures of ASC with EC as opposed to ASC alone. Others found activin A secretion by ASC when grown in co-culture with EC, leading to ASC differentiation into smooth muscle cells (Merfeld-Clauss et al., 2014) . Moreover, the anti-fibrotic follistatin was secreted more by tissue equivalents containing fibroblasts and EC than tissue equivalents containing ASC and EC. Our finding that recombinant follistatin reduced contraction of tissue equivalents containing ASC and EC is in line with others who observed a positive effect of follistatin on cutaneous wound healing in mice, where the addition of follistatin inhibited dermal scar formation (Bamberger et al., 2005) . Although follistatin binds activin A with the strongest affinity it is possible that follistatin also exerts its anti-fibrotic effect via sequestering of other proteins, such as activin B, GDF 8, 9, and 11 or BMP 4, 6, 7, and 15 (Amthor et al., 2004; Glister et al., 2004; Harrington et al., 2006; Otsuka et al., 2001; Schneyer et al., 2008) . However, the role in skin fibrosis of these proteins has not been investigated in detail.
In conclusion, our study shows that EC may play a critical role in fibrotic events, as seen in hypertrophic scars, by stimulating ASCmediated matrix contraction via reduction of follistatin. Further research into the regulatory function of follistatin in fibrosis could lead to new targets to improve or prevent skin fibrosis such as hypertrophic scars arising from deep wounds where adipose tissue is exposed.
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